$6.58
1.54% yesterday
Nasdaq, May 20, 10:15 pm CET
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Day One Biopharmaceuticals Inc Stock price

$6.58
-0.56 7.84% 1M
-7.04 51.69% 6M
-6.09 48.07% YTD
-9.39 58.80% 1Y
-0.62 8.61% 3Y
+5.53 526.67% 5Y
+5.53 526.67% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.10 1.54%
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Key metrics

Market capitalization $666.96m
Enterprise Value $196.86m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.22
P/S ratio (TTM) P/S ratio 4.12
P/B ratio (TTM) P/B ratio 1.39
Revenue (TTM) Revenue $161.92m
EBIT (operating result TTM) EBIT $-191.57m
Free Cash Flow (TTM) Free Cash Flow $-89.87m
Cash position $473.02m
EPS (TTM) EPS $-0.67
P/E forward negative
P/S forward 4.40
EV/Sales forward 1.30
Short interest 25.99%
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
89%
Hold
11%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
162 162
-
100%
- Direct Costs 8.16 8.16
1,890% 1,890%
5%
154 154
37,602% 37,602%
95%
- Selling and Administrative Expenses 115 115
39% 39%
71%
- Research and Development Expense 227 227
59% 59%
140%
-189 -189
17% 17%
-117%
- Depreciation and Amortization 2.81 2.81
585% 585%
2%
EBIT (Operating Income) EBIT -192 -192
16% 16%
-118%
Net Profit -69 -69
67% 67%
-43%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Neutral
Seeking Alpha
14 days ago
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara B...
Neutral
GlobeNewsWire
14 days ago
OJEMDA™  (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™  (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif.
Neutral
GlobeNewsWire
29 days ago
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial re...
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 181
Founded 2018
Website www.dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today